TY - JOUR
T1 - Promising Rationally Derived Combination Therapy with PI3K and CDK4/6 Inhibitors
AU - Muranen, Taru
AU - Meric-Bernstam, Funda
AU - Mills, Gordon B.
PY - 2014/7/14
Y1 - 2014/7/14
N2 - In this issue of Cancer Cell, Vora and colleagues demonstrate that persistent CDK4 and pRB activation underlie acquired resistance to phosphatidylinositol 3-kinase (PI3K) inhibitors in breast cancer cell lines, suggesting that clinical evaluation of rational combination therapy with PI3K and CDK4/6 inhibitors to mitigate resistance to PI3K inhibition is warranted. In this issue of Cancer Cell, Vora and colleagues demonstrate that persistent CDK4 and pRB activation underlie acquired resistance to phosphatidylinositol 3-kinase (PI3K) inhibitors in breast cancer cell lines, suggesting that clinical evaluation of rational combination therapy with PI3K and CDK4/6 inhibitors to mitigate resistance to PI3K inhibition is warranted.
AB - In this issue of Cancer Cell, Vora and colleagues demonstrate that persistent CDK4 and pRB activation underlie acquired resistance to phosphatidylinositol 3-kinase (PI3K) inhibitors in breast cancer cell lines, suggesting that clinical evaluation of rational combination therapy with PI3K and CDK4/6 inhibitors to mitigate resistance to PI3K inhibition is warranted. In this issue of Cancer Cell, Vora and colleagues demonstrate that persistent CDK4 and pRB activation underlie acquired resistance to phosphatidylinositol 3-kinase (PI3K) inhibitors in breast cancer cell lines, suggesting that clinical evaluation of rational combination therapy with PI3K and CDK4/6 inhibitors to mitigate resistance to PI3K inhibition is warranted.
UR - http://www.scopus.com/inward/record.url?scp=84904244868&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84904244868&partnerID=8YFLogxK
U2 - 10.1016/j.ccr.2014.06.020
DO - 10.1016/j.ccr.2014.06.020
M3 - Short survey
C2 - 25026206
AN - SCOPUS:84904244868
SN - 1535-6108
VL - 26
SP - 7
EP - 9
JO - Cancer cell
JF - Cancer cell
IS - 1
ER -